Overweight and obesity in Jordanian adults before and after COVID-19: a multi-index comparison.

Publication date: May 21, 2026

The prevalence of overweight and obesity has increased globally after COVID-19, including in Jordan. This study aimed to assess the prevalence of overweight and obesity among Jordanian adults using multiple anthropometric indicators. A cross-sectional study was conducted among 2,633 adults aged 18-65 (1,027 males; 1,606 females). Trained nutritionists collected anthropometric and body composition measurements, including body weight, height, waist circumference (WC), body mass index (BMI), waist-to-hip ratio (WHR), and waist-to-height ratio (WHtR) using a structured survey. Obesity was calculated using both global and Jordan-specific cut-offs. The prevalence of overweight and obesity varied by indicator, ranging from 41. 7% (WHtR using Jordan-specific cut-offs) to 72. 9% (body fat percentage). BMI-defined obesity affected 70-73% of both sexes. Central obesity was more prevalent in females (46. 9-73. 2%) compared to males (38. 8-65. 3%). Females had significantly higher odds of central obesity (OR = 2. 23-2. 48), whereas males showed higher odds when obesity was assessed using WHR, WHtR, and body-fat measures. Trends from 2009 to 2024 indicate persistently high prevalence rates, with slight declines in BMI- and WHtR-based obesity, while central obesity remained elevated, particularly among females. Obesity remains highly prevalent among Jordanian adults, with notable sex-specific differences, especially in central adiposity. Public health interventions should target high-risk groups and incorporate multiple anthropometric indicators along with sex- specific prevention and surveillance strategies.

Open Access PDF

Concepts Keywords
Global BMI
Nutritionists Body fat%
Obesity Obesity
Waist-to-height ratio
Waist-to-hip ratio

Semantics

Type Source Name
disease MESH Overweight
disease MESH obesity
disease MESH COVID-19
disease MESH body weight
disease MESH Central obesity
pathway REACTOME Reproduction
disease MESH included
drug DRUGBANK Coenzyme M
disease MESH chronic conditions
disease MESH alcoholic fatty liver
disease MESH NAFLD
disease MESH cardiovascular diseases
disease MESH T2D
disease MESH malignancies
disease MESH underweight
drug DRUGBANK BIA
disease MESH death
drug DRUGBANK Methionine
disease MESH face

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *